financetom
Business
financetom
/
Business
/
Union Pacific CEO says he had talks with Trump on $85 billion plan to buy Norfolk
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Union Pacific CEO says he had talks with Trump on $85 billion plan to buy Norfolk
Sep 12, 2025 11:58 AM

NEW YORK, Sept 12 (Reuters) - Union Pacific Corp ( UNP )

CEO Jim Vena met with U.S. President Donald Trump in the Oval

Office to discuss the railroad's proposed $85 billion buyout of

Norfolk Southern Corp ( NSC ), the company said on Friday, as it

awaits regulatory approval for what could be the U.S. freight

rail industry's most significant consolidation in decades.

White House support could accelerate the lengthy review process

despite resistance from rivals and pushback from shippers

concerned about reduced competition.

The White House did not immediately respond to a request

for comment.

The merger, if approved, could reshape the U.S. freight rail

industry by creating the first coast-to-coast single-line

network, streamlining operations and eliminating interchange

delays in key hubs like Chicago.

According to a company statement, Trump and Vena discussed

"how creating an American transcontinental railroad is a win for

U.S. competition, consumers, and the unionized workers whose

jobs will be protected when the merger is approved."

At a Morgan Stanley conference on Wednesday, Vena said he had

meetings with senior administration officials, without naming

them. "They see the strategic value in what we're proposing.

It's a clear win for the country," he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioAtla's Ozuriftamab Vedotin Receives FDA Fast-Track Designation; Shares Rise
BioAtla's Ozuriftamab Vedotin Receives FDA Fast-Track Designation; Shares Rise
Jul 23, 2024
09:38 AM EDT, 07/23/2024 (MT Newswires) -- BioAtla ( BCAB ) said Tuesday that the US Food and Drug Administration has granted fast-track designation to ozuriftamab vedotin, the company's drug candidate to treat patients with squamous cell carcinoma of the head and neck. The designation applies to drugs that are intended to treat a serious or life-threatening disease or condition,...
--FTC Seeking Info From JPMorgan, Mastercard on 'Surveillance Pricing'
--FTC Seeking Info From JPMorgan, Mastercard on 'Surveillance Pricing'
Jul 23, 2024
09:36 AM EDT, 07/23/2024 (MT Newswires) -- Price: 210.11, Change: -0.17, Percent Change: -0.08 ...
US FTC looking into targeted pricing based on personal data
US FTC looking into targeted pricing based on personal data
Jul 23, 2024
(Reuters) - The U.S. Federal Trade Commission has launched a study of products that could allow companies to set different prices for consumers based on their locations, past purchases, and other personal data. The agency said on Tuesday it had ordered Mastercard ( MA ), JPMorgan Chase ( JPM ), and six other companies to provide information about targeted pricing...
BridgeBio Pharma Names New COO
BridgeBio Pharma Names New COO
Jul 23, 2024
09:38 AM EDT, 07/23/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) Tuesday morning said it has appointed Thomas Trimarchi to the newly created position of chief operating officer at the biopharmaceuticals company. Trimarchi, who joined BridgeBio in 2018, most recently served as chief product officer. BridgeBio shares were slipping 1.8% soon after Tuesday's opening bell. Price: 26.20, Change: -0.47,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved